Board appointment puts governance in focus for Tarsus Pharmaceuticals

Tarsus Pharmaceuticals (TARS) has drawn fresh investor attention after appointing former Allergan CEO David Pyott to its Board of Directors, just days before reporting Q4 2025 results and providing an update on commercialization progress.

The appointment of David Pyott comes as Tarsus shares trade at US$66.61, with a 1 day share price return of 1.63% and a 7 day share price return of 9.59% following a weaker 90 day stretch. The 1 year total shareholder return of 39.23% and very large 3 year total shareholder return suggest longer term momentum has been strong.

If this board change has you thinking more broadly about where growth-focused capital might go next, it could be worth scanning our 27 healthcare AI stocks identified by the Simply Wall St screener.

With Tarsus trading at US$66.61 and sitting at a sizeable discount to the US$92.50 analyst price target, the key question is whether this reflects undervaluation or whether the market has already captured the company’s future growth.

Most Popular Narrative: 23.9% Undervalued

With Tarsus Pharmaceuticals last closing at $66.61 and the most followed narrative pointing to a fair value of $87.50, the gap between price and expectations is clear and puts the focus on what is driving that valuation.

Analysts have modestly reaffirmed their outlook on Tarsus Pharmaceuticals, maintaining the fair value estimate at approximately 87.50 dollars. They continue to anticipate robust, high margin revenue growth supported by strong, long term fundamentals.

Want to see what sits behind that confidence? The narrative leans on rapid revenue expansion, rising margins, and a future earnings profile that assumes sustained commercial traction. Curious how those pieces fit together into that fair value number?

Result: Fair Value of $87.50 (UNDERVALUED)

However, this depends on XDEMVY sustaining strong uptake, and on high spending on sales and advertising translating into lasting prescription growth; otherwise, margins and earnings could fall short.

Another View: Price Versus Sales Paints A Tougher Picture

So far, the story leans on fair value estimates and future cash flows that point to Tarsus as undervalued. A simpler lens tells a different story. On a P/S basis of 7.7x, Tarsus is priced well above the 4.4x US Pharmaceuticals average, which raises questions about how much optimism is already built into the current price.

If you prefer to lean on current revenue and market comparisons rather than long term projections, our valuation breakdown based on this ratio can help frame that trade off more clearly. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution has you thinking harder about Tarsus, take a moment to review the numbers yourself and pressure test the story. To see what the market currently views as the key positives, check out the 3 key rewards.

Looking for more investment ideas?

If Tarsus is on your radar, do not stop there. Use the screener to quickly surface other opportunities that match the kind of portfolio you want to build.

• Target potential value opportunities by scanning our 54 high quality undervalued stocks that pair solid fundamentals with attractive pricing signals.
• Strengthen your income stream by reviewing 15 dividend fortresses featuring companies that combine higher yields with an emphasis on resilience.
• Spot potential up and comers early with our screener containing 23 high quality undiscovered gems before they appear on everyone else’s watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.